Development and Medical Affairs Department Director, Elsa joined Nanobiotix in 2008, after having worked for the Oncology R&D Department of Sanofi-Aventis. She successfully managed clinical trials throughout the world of major oncology drugs up to their registrations. Elsa started working in the pharmaceutical industry in 1996 in the area of drug safety, primarily in oncology. Since 1999, she has been working on pivotal clinical trials, in particular for treatment of colon cancer, breast cancer and prostate cancer. Dr. Borghi has also worked on soft tissue sarcoma, lung cancer and Phase I trials involving chemotherapy, anti-neovascularisation agents and targeted therapies. Elsa received her MD from the University of Cordoba, Spain – School of Medicine in March 1984 and a obtained the French equivalent in 1994 from the University of Paris V, extended by a specialisation in human genetics in 1995. In parallel to her degree in medicine, she also obtained an MSc in Biological Sciences from the University of Paris VI.

oncology drugs soft tissue sarcoma, lung cancer and Phase I trials involving chemotherapy, anti-neovascularisation agents and targeted therapies